Insider Transactions in Q1 2023 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2023
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
127,221
+3.19%
|
$763,326
$6.76 P/Share
|
|
Mar 21
2023
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,000
-2.55%
|
$1,860,000
$62.74 P/Share
|
|
Mar 21
2023
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+2.49%
|
$60,000
$2.67 P/Share
|
|
Mar 17
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.46%
|
$80,000
$64.03 P/Share
|
|
Mar 17
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.46%
|
$2,500
$2.67 P/Share
|
|
Mar 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.16%
|
$756,000
$63.79 P/Share
|
|
Mar 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.76%
|
$37,000
$2.67 P/Share
|
|
Mar 03
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.17%
|
$315,000
$63.84 P/Share
|
|
Mar 03
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+5.81%
|
$75,000
$15.09 P/Share
|
|
Mar 01
2023
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Direct |
500
-0.38%
|
$32,500
$65.33 P/Share
|
|
Feb 27
2023
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+8.03%
|
$300,000
$3.76 P/Share
|
|
Feb 23
2023
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,104
-2.6%
|
$75,072
$68.76 P/Share
|
|
Feb 23
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,646
-2.96%
|
$111,928
$68.76 P/Share
|
|
Feb 21
2023
|
Karen Lewis Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
553
-1.28%
|
$32,074
$58.5 P/Share
|
|
Feb 21
2023
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,628
+13.33%
|
-
|
|
Feb 21
2023
|
Nur Nicholson Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
825
-1.28%
|
$47,850
$58.5 P/Share
|
|
Feb 21
2023
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,886
+13.32%
|
-
|
|
Feb 21
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
825
-1.46%
|
$47,850
$58.5 P/Share
|
|
Feb 21
2023
|
Jeffrey Eisele Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,886
+14.92%
|
-
|
|
Feb 21
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
441
-0.85%
|
$25,578
$58.5 P/Share
|
|
Feb 21
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,280
+9.25%
|
-
|
|
Feb 21
2023
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
715
-1.02%
|
$41,470
$58.5 P/Share
|
|
Feb 21
2023
|
Lukas Scheibler Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,886
+12.32%
|
-
|
|
Feb 21
2023
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,602
-0.15%
|
$92,916
$58.5 P/Share
|
|
Feb 21
2023
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,908
+1.31%
|
-
|
|
Feb 21
2023
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
825
-0.47%
|
$47,850
$58.5 P/Share
|
|
Feb 21
2023
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,886
+5.32%
|
-
|
|
Feb 21
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
974
-0.72%
|
$56,492
$58.5 P/Share
|
|
Feb 21
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,683
+7.97%
|
-
|
|
Feb 21
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,195
-0.12%
|
$69,310
$58.5 P/Share
|
|
Feb 21
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,886
+0.96%
|
-
|
|
Feb 21
2023
|
James George Chopas VP/Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
334
-1.07%
|
$19,372
$58.5 P/Share
|
|
Feb 21
2023
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,044
+11.48%
|
-
|
|
Feb 21
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,041
-1.35%
|
$60,378
$58.5 P/Share
|
|
Feb 21
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,886
+11.37%
|
-
|
|
Feb 17
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.46%
|
$65,000
$52.38 P/Share
|
|
Feb 17
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.46%
|
$2,500
$2.67 P/Share
|
|
Feb 10
2023
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
532
-0.32%
|
$27,132
$51.21 P/Share
|
|
Feb 10
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
975
-0.79%
|
$49,725
$51.21 P/Share
|
|
Feb 10
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
782
-1.15%
|
$39,882
$51.21 P/Share
|
|
Feb 10
2023
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
678
-1.11%
|
$34,578
$51.21 P/Share
|
|
Feb 10
2023
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,958
-0.38%
|
$201,858
$51.21 P/Share
|
|
Feb 10
2023
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
670
-1.42%
|
$34,170
$51.21 P/Share
|
|
Feb 10
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,134
-0.11%
|
$57,834
$51.21 P/Share
|
|
Feb 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.18%
|
$648,000
$54.45 P/Share
|
|
Feb 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.78%
|
$37,000
$2.67 P/Share
|
|
Feb 03
2023
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.86%
|
$275,000
$55.85 P/Share
|
|
Feb 03
2023
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.42%
|
$75,000
$15.09 P/Share
|
|
Feb 01
2023
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Direct |
500
-0.38%
|
$26,000
$52.61 P/Share
|
|
Jan 30
2023
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
883
-1.86%
|
$45,916
$52.76 P/Share
|